Details for New Drug Application (NDA): 021880
✉ Email this page to a colleague
The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the lenalidomide profile page.
Summary for 021880
Tradename: | REVLIMID |
Applicant: | Bristol Myers Squibb |
Ingredient: | lenalidomide |
Patents: | 3 |
Suppliers and Packaging for NDA: 021880
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
REVLIMID | lenalidomide | CAPSULE;ORAL | 021880 | NDA | Celgene Corporation | 59572-402 | 59572-402-00 | 100 CAPSULE in 1 BOTTLE (59572-402-00) |
REVLIMID | lenalidomide | CAPSULE;ORAL | 021880 | NDA | Celgene Corporation | 59572-402 | 59572-402-28 | 28 CAPSULE in 1 BOTTLE (59572-402-28) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 5MG | ||||
Approval Date: | Dec 27, 2005 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | May 28, 2026 | ||||||||
Regulatory Exclusivity Use: | INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL) | ||||||||
Regulatory Exclusivity Expiration: | May 28, 2026 | ||||||||
Regulatory Exclusivity Use: | INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL) | ||||||||
Regulatory Exclusivity Expiration: | Feb 22, 2024 | ||||||||
Regulatory Exclusivity Use: | TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT) |
Expired US Patents for NDA 021880
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-002 | Dec 27, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription